These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33045661)

  • 1. Current development of CBP/p300 inhibitors in the last decade.
    He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
    Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
    Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
    J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
    Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
    Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
    Chaikuad A; Lang S; Brennan PE; Temperini C; Fedorov O; Hollander J; Nachane R; Abell C; Müller S; Siegal G; Knapp S
    J Med Chem; 2016 Feb; 59(4):1648-53. PubMed ID: 26731131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
    Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
    Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unravelling novel congeners from acetyllysine mimicking ligand targeting a lysine acetyltransferase PCAF bromodomain.
    Suryanarayanan V; Singh SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4303-4319. PubMed ID: 29228881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.
    Zucconi BE; Makofske JL; Meyers DJ; Hwang Y; Wu M; Kuroda MI; Cole PA
    Biochemistry; 2019 Apr; 58(16):2133-2143. PubMed ID: 30924641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
    Strachowska M; Robaszkiewicz A
    Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
    Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
    J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome.
    Weinert BT; Narita T; Satpathy S; Srinivasan B; Hansen BK; Schölz C; Hamilton WB; Zucconi BE; Wang WW; Liu WR; Brickman JM; Kesicki EA; Lai A; Bromberg KD; Cole PA; Choudhary C
    Cell; 2018 Jun; 174(1):231-244.e12. PubMed ID: 29804834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors.
    Xiong Y; Zhang M; Li Y
    Curr Med Chem; 2020; 27(33):5583-5598. PubMed ID: 31364510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment.
    Gou P; Zhang W
    Biomed Pharmacother; 2024 Feb; 171():116130. PubMed ID: 38215693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
    Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
    Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
    Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
    Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
    Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
    J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
    Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
    Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the reaction coordinate of the p300/CBP histone acetyltransferase with bisubstrate analogs.
    Karukurichi KR; Cole PA
    Bioorg Chem; 2011 Feb; 39(1):42-7. PubMed ID: 21111442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site.
    Ghizzoni M; Wu J; Gao T; Haisma HJ; Dekker FJ; George Zheng Y
    Eur J Med Chem; 2012 Jan; 47(1):337-44. PubMed ID: 22100137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
    Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.